COMP <GO>
GLUE vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
Monte Rosa Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GLUE 0
— LLY 6
■ METRIC PARITY
LAST: $10.76 (-1.01%) • MKT CAP: $927.4M
balance-sheet
—
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.29T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GLUE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GLUE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.64% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 32.36% | -67.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -2.97% | 2.30% | -5.27 | LLY | /fcf-yield <GO> |
| Operating Margin | — | 40.21% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 31.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 45.51% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | — | 9.29 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 9/9 | -6.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 66.6 | -20.40 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 30.6x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $927.4M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GLUE REV | LLY REV | GLUE GROSS % | LLY GROSS % | GLUE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $65.18B | — | 83.0% | -$27.5M | $16.81B |
| FY 2024 | $0 | $45.04B | — | 81.3% | $38.0M | $8.82B |
| FY 2023 | $0 | $34.12B | — | 79.3% | -$43.8M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GLUE // BETA —
LLY // BETA 0.51